^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TGFβ targeting CAR-T cells

    i
    Other names: TGFβ targeting CAR-T cells
    Associations

    News

    Trials
    Company:
    Hunan Yongren Medical Innovation, Zhaotai InVivo Biomedicine
    Drug class:
    TGFβ-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    6ms
    ZZCART-003: GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2029 --> Aug 2036 | Trial primary completion date: Aug 2025 --> Aug 2029
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    GPC3 (Glypican 3)
    |
    TGFβ targeting CAR-T cells
    almost2years
    GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression (clinicaltrials.gov)
    P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Trial completion date: Aug 2024 --> Aug 2029 | Trial primary completion date: Aug 2022 --> Aug 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
    |
    GPC3 (Glypican 3)
    |
    GPC3 expression • GPC3 positive
    |
    TGFβ targeting CAR-T cells